Researchers used elegant in vitro and in vivo mouse models to demonstrate that RHOJ is highly expressed in EMT tumor cells and modulates resistance to different chemotherapies, but further studies are still needed to validate their findings in clinical samples from patients with skin SCCs. This evidence concerns the gene RHOJ and neoplasm.